Differential effects of transferrin receptor blockade on the cellular mechanisms involved in graft rejection

Transplant Immunology

Volumn 7, Issue 3, 1999, Pages 131-139

  Bayer, Allison L ^a   Baliga, Prabhakar ^a   Woodward, Jennifer E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CELL SURFACE RECEPTOR; INTERLEUKIN 15; INTERLEUKIN 4; MESSENGER RNA; MONOCLONAL ANTIBODY; TRANSFERRIN RECEPTOR;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART GRAFT; MIXED LYMPHOCYTE REACTION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; T LYMPHOCYTE ACTIVATION;

EID: 0032695103     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(99)80032-X     Document Type: Article

References (31)

1. May WS Jr., Cuatrecasas P. Transferrin receptor: its biological significance. J Membr Biol. 88:1985;205-215.
2. Huebers HA, Finch CA. The physiology of transferrin and transferrin receptors. Physiol Rev. 67:1987;520-582.
3. Neckers LM. Regulation of transferrin receptor expression and control of cell growth. Pathobiology. 59:1991;11-18.
4. Pattanapanyasat K, Hoy TG. Expression of cell surface transferrin receptor and intracellular ferritin after in vitro stimulation of peripheral blood T lymphocytes. Eur J Haematol. 47:1991;140-145.
5. Galbraith RM, Werner P, Arnaud P, Galbraith GM. Transferrin binding to peripheral blood lymphocytes activated by phytohemagglutinin involves a specific receptor. Ligand interaction. J Clin Invest. 66:1980;1135-1143.
6. Marrack P, Kappler J. The T cell receptor. Science. 238:1987;1073-1079.
7. Bierer BE, Burakoff SJ. T-lymphocyte activation: the biology and function of CD2 and CD4. Immunol Rev. 111:1989;267-294.
8. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol. 7:1989;445-480.
9. Weiss A. Structure and function of the T cell antigen receptor. J Clin Invest. 86:1990;1015-1022.
10. Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell. 76:1994;263-274.
11. Ledbetter JA, Imboden JB, Schieven GL, et al. CD28 ligation in T-cell activation: evidence for two signal transduction pathways. Blood. 75:1990;1531-1539.
12. Teixeira S, Kuhn LC. Post-transcriptional regulation of the transferrin receptor and 4F2 antigen heavy chain mRNA during growth activation of spleen cells. Eur J Biochem. 202:1991;819-826.
13. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 136:1986;2348-2357.
14. Romagnani S. The Th1/Th2 paradigm. Immunol Today. 18:1997;263-266.
15. Halloran PF, Broski AP, Batiuk TD, Madrenas J. The molecular immunology of acute rejection: an overview. Transpl Immunol. 1:1993;3-27.
16. Sauvage CA, Mendelsohn JC, Lesley JF, Trowbridge IS. Effects of monoclonal antibodies that block transferrin receptor function on the in vivo growth of a syngeneic murine leukemia. Cancer Res. 47:1987;747-753.
17. Kudoh S, Stanley J, Edinger MG, et al. T lymphocytes infiltrating renal cell carcinoma have a reduced expression of transferrin receptor. Int J Cancer. 58:1994;369-375.
18. Woodward JE, Bayer AL, Chavin KD, Boleza KA, Baliga P. Anti-transferrin receptor monoclonal antibody: a novel immunosuppressant. Transplantation. 65:1998;6-9.
19. Bayer AL, Baliga P, Woodward JE. Transferrin receptor in T cell activation and transplantation. J Leukocyte Biol. 64:1998;19-24.
20. Lesley JF, Schulte RJ. Inhibition of cell growth by monoclonal anti-transferrin receptor antibodies. Mol Cell Biol. 5:1985;1814-1821.
21. Aihara Y, Buhring HJ, Aihara M, Klein J. An attempt to produce 'pre-T' cell hybridomas and to identify their antigens. Eur J Immunol. 16:1986;1391-1399.
22. Judd KP, Trentin JJ. Cardiac transplantation in mice. I. Factors influencing the take and survival of heterotopic grafts. Transplantation. 11:1971;298-302.
23. Carlquist JF, Edelman LS, White W, Shelby J, Anderson JL. Cytokines and rejection of mouse cardiac allografts. Transplantation. 62:1996;1160-1166.
24. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 381:1996;434-438.
25. Finberg R, Burakoff SJ, Benacerraf B, Greene MI. The cytolytic T lymphocyte response to trinitrophenyl-modified syngeneic cell. II. Evidence for antigen-specific suppressor T cells. J Immunol. 123:1979;1210-1214.
26. Arrigo SJ, Weitsman S, Rosenblatt JD, Chen IS. Analysis of rev gene function on human immunodeficiency virus type 1 replication in lymphoid cells by using a quantitative polymerase chain reaction method. J Virol. 63:1989;4875-4881.
27. Baliga P, Chavin KD, Qin L, et al. CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity. Transplantation. 58:1994;1082-1090.
28. Woodward JE, Bayer AL, Chavin KD, Blue ML, Baliga P. T-cell alterations in cardiac allograft recipients after B7 (CD80 and CD86) blockade. Transplantation. 66:1998;14-20.
29. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity. 7:1997;445-450.
30. Sayegh MH, Akalin E, Hancock WW, et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med. 181:1995;1869-1874.
31. Takeuchi T, Lowry RP, Konieczny B. Heart allografts in murine systems. The differential activation of Th2-like effector cells in peripheral tolerance. Transplantation. 53:1992;1281-1294.